When we use androgen deprivation therapy, we are lowering testosterone levels typically by turning off the testes from making testosterone. This starves cancer cells, causing them to shut down, ...

Androgen deprivation therapy (ADT) for prostate cancer is associated with decreased bone mineral density (BMD) in patients. This decreased BMD can lead to an increased risk of fractures and ...

Androgen deprivation therapy is commonly used to treat prostate cancer, often on an open-ended basis for therapy of advanced prostate cancer. It is estimated that 44 percent of men with prostate ...

Introduction In 1941, Huggins demonstrated the critical role of androgens in stimulating prostate cancer (PC) growth, providing the foundation for androgen-deprivation therapy (ADT) for metastatic PC.

The constant threat of recurrence feels like the proverbial sword of Damocles — always present, always waiting. If my cancer does return, the now-inert metal seeds scattered through my prostate and ...

Androgen deprivation therapy suppresses the production of testosterone, the male hormone said to fuel growth of prostate cancer. The therapy improves survival when given with radiation for later ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

PCa is now the most common cancer in men in the United States, and androgen-deprivation therapy (ADT) is the mainstay of treatment for locally advanced and metastatic PCa. 2, 3 Testosterone, the main ...

Platelets, Chromogranin A, and C-Reactive Protein Predict Therapy Failure of Metastatic Hormone-Sensitive Prostate Cancer while miR-375 Outperforms Prostate-Specific Antigen in Stratifying ...

Earlier this year, the addition of Nubeqa to docetaxel and androgen deprivation therapy was shown to lower hospitalization rates among patients with metastatic hormone-sensitive prostate cancer but ...

Androgen Deprivation Therapy and Prostate Cancer: Bone Health, Survivorship, and Side Effects Sandhya Srinivas, MD; Rana R. McKay, MD Disclosures July 19, 2023 0 ...